Intermittent Low-dose Ritlecitinib in Refractory Paediatric Alopecia Areata: A Case Report with Therapeutic Implications
DOI:
https://doi.org/10.2340/actadv.v105.43607Keywords:
Alopecia Areata, ritlecitinib, pre-school children, Treatment, SafetyDownloads
References
Lee HH, Gwillim E, Patel KR, Hua T, Rastogi S, Ibler E, et al. Epidemiology of alopecia areata, ophiasis, totalis, and universalis: a systematic review and meta-analysis. J Am Acad Dermatol 2020; 82: 675–682.
https://doi.org/10.1016/j.jaad.2019.08.032 DOI: https://doi.org/10.1016/j.jaad.2019.08.032
Gonzalez ME, Browning J, Smith S, Plotka A, Zhu JD, Parvatini S, et al. A phase 1, open-label study of the pharmacokinetics of ritlecitinib in children aged 6–12 years with alopecia areata. Pediatr Dermatol 2025, Feb 9. [Online ahead of print]
https://doi.org/10.1111/pde.15895 DOI: https://doi.org/10.1111/pde.15895
Huang J, Jian J, Li M, Ji R, Li J, Shi W. Effectiveness and tolerability of ritlecitinib in children with alopecia areata: a case series. J Am Acad Dermatol 2025; 92: 1395–1397.
https://doi.org/10.1016/j.jaad.2025.01.090 DOI: https://doi.org/10.1016/j.jaad.2025.01.090
Published
How to Cite
License
Copyright (c) 2025 Yunhan Hu, Cuilin Xie, Mengyao Hu, Yongjun Chen, Ting Yang

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.